Edition:
United Kingdom

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

12.75USD
12 Dec 2017
Change (% chg)

$0.20 (+1.59%)
Prev Close
$12.55
Open
$12.65
Day's High
$13.15
Day's Low
$12.65
Volume
130,747
Avg. Vol
202,036
52-wk High
$19.90
52-wk Low
$11.85

Select another date:

Wed, Nov 1 2017

BRIEF-Momenta Pharma says Q3 loss per share $0.44

* Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

BRIEF-Momenta And Mylan report initial results from phase 1 clinical trial for M834

* Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept)

BRIEF-Momenta Pharmaceuticals posts Q2 loss per share $0.50

* Momenta pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc

* Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

UPDATE 2-U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 Amphastar Pharmaceuticals Inc on Friday won a trial in a lawsuit claiming that the drugmaker through its production of a generic version of the blood-thinner Lovenox infringed a patent held by Momenta Pharmaceuticals Inc.

Select another date: